Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation.

Non-Hodgkin's lymphoma (NHL) has been increasing in frequency in the industrialized world, but the environmental and genetic factors that contribute to susceptibility are not known. B-cell lymphomas represent a major cause of morbidity and mortality in HIV-infected individuals. The identification of a deletion in the CCR5 chemokine receptor gene that alters the risk for infection and progression to AIDS led us to examine a potential role of this gene in AIDS lymphoma. A matched case-control analysis was performed using all eligible NHL cases in the Multicenter AIDS Cohort Study. Patients were matched for age, study center, time AIDS-free, and slope of the CD4+ T-cell decline. The CCR5-delta32 allele was found to be associated with a 3-fold lower risk of NHL among individuals after controlling for time of infection and progression toward AIDS. The CCR5 gene was not associated with a difference in risk for Kaposi's sarcoma, another common malignancy in AIDS patients, or opportunistic infections. Costimulation of normal phorbol 12-myristate 13-acetate-treated B cells with the CCR5 ligand RANTES induced a proliferative response, indicating that RANTES is a mitogen for B cells. Taken together, these findings suggest that the CCR5 gene plays a role in the risk of NHL in HIV-infected patients, perhaps through a mechanism involving a decreased response of B cells to the mitogenic activity of RANTES.

[1]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[2]  D. Littman.  Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[3]  Cairns Js,et al.  Chemokines and HIV-1 second receptors: The therapeutic connection , 1998 .

[4]  G. Gaidano,et al.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity. , 1998, The American journal of pathology.

[5]  J. Phair,et al.  A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation , 1998, Nature Medicine.

[6]  Kuan-Teh Jeang,et al.  Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.

[7]  H. Schuitemaker,et al.  Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.

[8]  H. Sheppard,et al.  The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression , 1997, Nature Medicine.

[9]  D. Straus.  HIV-associated lymphomas. , 1997, Current oncology reports.

[10]  J J Goedert,et al.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.

[11]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[12]  V. Harden,et al.  Chemokines and HIV–1 second receptors , 1996, Nature Medicine.

[13]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[14]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[15]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[16]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[17]  P. Gray,et al.  Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1β, and MIP-1α* , 1996, The Journal of Biological Chemistry.

[18]  J. Chmiel,et al.  Re: "Risk factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS)". , 1996, American journal of epidemiology.

[19]  B. Premack,et al.  Activation of dual T cell signaling pathways by the chemokine RANTES. , 1995, Science.

[20]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  J. Margolick,et al.  Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. , 1990, Clinical immunology and immunopathology.

[22]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[23]  H. Tulinius.  [Epidemiology of non-Hodgkin's lymphoma]. , 1977, Strahlentherapie.

[24]  S. Staszewski,et al.  Increased serum and mRNA levels of RANTES associated with elevated levels of activated CD8+CD38+ T cells in HIV-1 infected individuals. , 1997, Intervirology.

[25]  D. Weissman,et al.  Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk , 1997, Molecular medicine.

[26]  J. Margolick,et al.  Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. , 1993, Cytometry.

[27]  J. Phair,et al.  Recent Scientific Contributions to Understanding HIV/AIDS from the Multicenter AIDS Cohort Study , 1992 .

[28]  J. Chmiel,et al.  Estimation of time since exposure for a prevalent cohort. , 1992, Statistics in medicine.